Medicine and Dentistry
ACE Inhibitor
7%
Acetazolamide
14%
Acute Decompensated Heart Failure
85%
Adrenomedullin
8%
Amino Terminal Sequence
10%
Arm
9%
Biological Marker
14%
Brain Natriuretic Peptide
11%
Cardiovascular System
6%
Combination Therapy
17%
Congestive Heart Failure
17%
Creatinine
6%
Diuretic Agent
27%
Drug Megadose
6%
Drug Therapy
7%
Ejection Fraction
17%
Glomerular Filtration Rate
12%
Hazard Ratio
9%
Heart Failure
92%
Heart Failure with Reduced Ejection Fraction
11%
Heart Left Ventricle Ejection Fraction
7%
Kidney Function
26%
Loop Diuretic Agent
15%
Mineralocorticoid Antagonist
7%
Natriuresis
9%
Pathophysiology
8%
Placebo
5%
Prevalence
5%
Proenkephalin
6%
Quality of Life
6%
Titrimetry
16%
Urinary System
9%
Volume Overload
9%
Keyphrases
Acetazolamide
14%
Acute Decompensated Heart Failure
13%
Acute Heart Failure
66%
All-cause Mortality
9%
Angiotensin Receptor Blockers
6%
Atrial Fibrillation
9%
Beta-blockers
6%
Biology Study
5%
Chronic Heart Failure
15%
Clinical Outcomes
15%
Confidence Interval
9%
Congestion
10%
Decongestion
18%
Diuretic Response
9%
Diuretics
5%
Ejection Fraction
5%
Enkephalin
6%
Estimated Glomerular Filtration Rate
7%
Failure Data
8%
Guideline-directed Medical Therapy
8%
Heart Failure
33%
Heart Failure Hospitalization
7%
Heart Failure Patients
9%
Heart Failure Trials
11%
Heart Failure with Preserved Ejection Fraction (HFpEF)
17%
High-intensity Care
14%
Hospitalization
5%
Left Ventricular Ejection Fraction
6%
Loop Diuretics
6%
Mineralocorticoid Receptor Antagonists
6%
N-terminal Pro-brain Natriuretic Peptide (NT-proBNP)
11%
Natriuresis
7%
Patients with Heart Failure
23%
Preserved Ejection Fraction
6%
Prognostic Value
5%
Randomized Clinical Trial
5%
Renal Disease
5%
Renal Function
15%
Renal Function Improvement
10%
Residual Congestion
6%
Tailored Treatment
5%
Up-titration
17%
Usual Care
6%
Volume Overload
10%
Pharmacology, Toxicology and Pharmaceutical Science
Acetazolamide
14%
Acute Heart Failure
88%
Adrenomedullin
8%
Aldosterone
6%
All Cause Mortality
10%
Angiotensin
6%
Angiotensin Receptor Antagonist
6%
Atrial Fibrillation
6%
Biological Marker
15%
Brain Natriuretic Peptide
9%
Combination Therapy
15%
Congestive Heart Failure
18%
Creatinine
8%
Dipeptidyl Carboxypeptidase Inhibitor
9%
Diuretic Agent
28%
Heart Failure
100%
Heart Failure with Preserved Ejection Fraction
5%
Heart Failure with Reduced Ejection Fraction
10%
Hypochloremia
7%
Inflammation
6%
Loop Diuretic Agent
19%
Mineralocorticoid Antagonist
6%
Pathophysiology
7%
Placebo
8%
Prevalence
5%
Proenkephalin
6%
Renin
6%
